The first approved biologics targeting inflammatory pathways in COPD, dupilumab (an anti–IL-4R/IL-13R) and mepolizumab (an anti–IL-5), are indicated for use in adults with inadequately controlled COPD and an eosinophilic phenotype. Here, IL4R is linked to chronic obstructive pulmonary disease.